A Phase 3 Randomized, Double-Blind, Active-Controlled, Parallel-Group,
Research payments
$1,154,111
Through program year 2023, $1,154,111 in research payments was reported against A Phase 3 Randomized, Double-Blind, Active-Controlled, Parallel-Group,, across 233 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $2,015 | 2 |
| 2022 | Research | $442 | 1 |
| 2021 | Research | $100,243 | 17 |
| 2020 | Research | $254,443 | 63 |
| 2019 | Research | $796,968 | 150 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Sagar Panse Macon, GA Named on 24 payments
- Arnold Silva Meridian, ID Named on 20 payments
- Jesus Navarro Tampa, FL Named on 17 payments
- V. Subramanian Alexandria, VA Named on 17 payments
- Marializa Bernardo Houston, TX Named on 14 payments
- Hemant Dhingra Fresno, CA Named on 13 payments
- Jayant Kumar Albuquerque, NM Named on 10 payments
- Daniel Coyne Saint Louis, MO Named on 9 payments
- Fabiola Schlessinger West Palm Beach, FL Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.